DTU
DTU

Conference abstracts (28 of 182)

Years :

Search conference abstracts :

2017

Diabetes UK Annual Professional Conference, Manchester
Sensing hypoglycaemia at an earlier stage using an integrated physiological multi-signal data fusion approach
MJ Theodorakis, D Clifton, GW Colopy, J Jorge, A Dhere, C Ballav, I Kennedy, O Agbaje, L Tarassenko, RR Holman
Diabetic Medicine 2017;34 (Suppl 1):62-63
[Abstract]

Diabetes UK Annual Professional Conference, Manchester
Development of an online risk calculator to predict durability of good glycaemic control with sulfonylurea and thiazolidinedione therapy: a MASTERMIND stratified medicine study
JM Dennis, WE Henley, M Weedon, M Lonergan, AG Jones, N Sattar, RR Holman, ER Pearson, AT Hattersley, BM Shields and LR Rodgers
Diabetic Medicine 2017;34 (Suppl 1):5 - 35
[Abstract]

Diabetes UK Annual Professional Conference, Manchester
Predictors of response to SGLT2-inhibitors and DPP4-inhibitors: a MASTERMIND stratified medicine study
B Shields, J Dennis, W Henley, M Weedon, M Lonergan, A Jones, N Sattar, R Holman, E Pearson and A Hattersley
Diabetic Medicine 2017;34 (Suppl 1):5 - 35
[Abstract]

Diabetes UK Annual Professional Conference, Manchester
Are the cardiovascular risk reductions seen with empagliflozin in the EMPA-REG OUTCOME trial explained by conventional cardiovascular risk factors?
RL Coleman, A Gray, UC Broedl, D Fitchett, JT George, HJ Woerle, B Zinman and RR Holman
Diabetic Medicine 2017;34 (Suppl 1):5 - 35
[Abstract]

Diabetes UK Annual Professional Conference, Manchester
Estimating the potential incremental benefits on Type 2 diabetes complications rates of targeting successively lower LDL-cholesterol levels
SA Mostafa, RL Coleman, OF Agbaje, A Gray, RR Holman and MA Bethel
Diabetic Medicine 2017;34 (Suppl 1):36-194
[Abstract]

53rd Annual Meeting of the European Association for the Study of Diabetes, Lisbon
Time to insulin in the Trial Evaluating Cardiovascular Outomes with Sitagliptin (TECOS)
S.S. Engel, M.A. Bethel, J. Garg, S.R. Stevens, Y. Lokhnygina3, R.G. Josse4, J.B. Green, E.D. Peterson, R.R. Holman
Diabetelogia 2017;60:(Suppl 1):S3
[Abstract]

53rd Annual Meeting of the European Association for the Study of Diabetes, Lisbon
Predicting post one-year durability of glucose-lowering monotherapies in patients with new-onset type 2 diabetes
O.F. Agbaje, R.L. Coleman, A.T. Hattersley, E.Z. Pearson, R.R. Holman
Diabetelogia 2017;60:(Suppl 1):S300
[Abstract]

53rd Annual Meeting of the European Association for the Study of Diabetes, Lisbon
Risk of anaemia with long-term metformin use in a community setting
L.A. Donnelly, K. Gardner, R.L. Coleman, N. Sattar, A.T. Hattersley, R.R. Holman, E.R. Pearson
Diabetelogia 2017;60:(Suppl 1):S139
[Abstract]

53rd Annual Meeting of the European Association for the Study of Diabetes, Lisbon
Associations between insulin dose titration over one year and hypoglycaemia: a descriptive study using 4-T data
A.J. Farmer, M.-M. Lee , J. Oke , A. Reutens , J. Shaw , R.R. Holman
Diabetelogia 2017;60:(Suppl 1):S310
[Abstract]

53rd Annual Meeting of the European Association for the Study of Diabetes, Lisbon
No major impact seen with sitagliptin on rates of cardiovascular death or hospitalisation for heart failure following myocardial infarction during TECOS
M.A. Nauck, K.S. Pieper, Y. Lokhnygina, D.K. McGuire, E.D. Peterson, R.R. Holman,
Diabetelogia 2017;60:(Suppl 1):S356
[Abstract]

53rd Annual Meeting of the European Association for the Study of Diabetes, Lisbon
Association between race and glycaemic response to sitagliptin: insights from TECOS
T.M.E. Davis, H. Mulder, Y. Lokhnygina, E. Standl, E.D. Peterson, R.R. Holman
Diabetelogia 2017;60:(Suppl 1):S356
[Abstract]

53rd Annual Meeting of the European Association for the Study of Diabetes, Lisbon
Resource use and UK-perspective costs in patients with type 2 diabetes during the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
A.M. Gray, J. Leal, S.D.Reed, Y. Li, F. Graham, J.B.Green, K.D. Kaufman, L. Radican, J. Alfredsson, J. Buse, A. Riefflin, F. Van de Werf, E.D. Peterson, R.R. Holman
Diabetelogia 2017;60:(Suppl 1):S357
[Abstract]

53rd Annual Meeting of the European Association for the Study of Diabetes, Lisbon
A calculator to predict durability of HbA1c response with DPP4 inhibitors, sulfonylureas and thiazolidinediones: a MASTERMIND precision medicine study
J.M. Dennis, W.E. Henley, M.N. Weedon, M. Lonergan, L.R. Rodgers, A.G. Jones, N.A. Sattar, R.R. Holman, E.R. Pearson, A.T. Hattersley, B.M. Shields
Diabetelogia 2017;60:(Suppl 1):S388
[Abstract]

53rd Annual Meeting of the European Association for the Study of Diabetes, Lisbon
Predictors of response to SGLT2-inhibitors and DPP4-inhibitors
B.M. Shields, J. Dennis, W. Henley, M.Weedon, M. Lonergan, L. Rodgers, A. Jones, N. Sattar, R. Holman, E. Pearson, A. Hattersley
Diabetelogia 2017;60:(Suppl 1):S404
[Abstract]

53rd Annual Meeting of the European Association for the Study of Diabetes, Lisbon
Are the cardiovascular risk reductions seen with empagliflozin in the EMPA-REG OUTCOME trial explained by conventional cardiovascular risk factors?
R.L. Coleman, A.M. Gray, U.C. Broedl, D. Fitchett, J.T. George, H.-J. Woerle, B. Zinman, R.R. Holman
Diabetelogia 2017;60:(Suppl 1):S522
[Abstract]

53rd Annual Meeting of the European Association for the Study of Diabetes, Lisbon
Modelling incremental benefits on macro- and micro-vascular complications rates when targeting lower systolic blood pressure levels in type 2 diabetes
S.A. Mostafa, R.L. Coleman, O.F. Agbaje, A. Gray, R.R. Holman, M.A. Bethel
Diabetelogia 2017;60:(Suppl 1):S525
[Abstract]

American Heart Association (AHA) Scientific Sessions 2017, Anaheim
Underuse of Oral Anticoagulation, High Use of Aspirin and Worse Clinical Outcomes in Patients With Type 2 Diabetes and Atrial Fibrillation: Insights From the TECOS Trial
Patricia Guimaraes, Renato D Lopes, Susanna R Stevens, Jennifer B Green, Darren K McGuire, Rury R Holman and Eric D Peterson, on behalf of the TECOS Study Group
Circulation 2017;136:Supp 1:
[Abstract]

American Heart Association (AHA) Scientific Sessions 2017, Anaheim
International Variation in Management and Clinical Outcome of Patients With Type 2 Diabetes and Heart Failure: Insights From TECOS
Ankeet S Bhatt, Nancy Luo, Nicole Solomon, Neha J Pagidipati, Giuseppe Ambrosio, Jennifer B Green, Darren K McGuire, Eberhard Standl, Jan H Cornel, Sigrun Halvorsen, Renato D Lopes, Harvey White, Rury R Holman, Eric D Peterson, and Robert J Mentz, on behalf of the TECOS Study Group
Circulation 2017;136:Suppl 1:
[Abstract]

American Heart Association (AHA) Scientific Sessions 2017, Anaheim
Effect of Exenatide Once-Weekly on Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease: Insights From the EXSCEL Trial
Robert J Mentz, M. Angelyn Bethel, Vivian P Thompson, Yuliya Lokhnygina, John B Buse, Julian C Chan, Jasmine Choi, Stephanie M Gustavson, Nayyar Iqbal, Aldo P Maggioni, Steven P Marso, Peter Öhman, Neha J Pagidipati, Neil Poulter, Ambady Ramachandran, Bernard Zinman, Rury R Holman, Adrian F Hernandez, on behalf of the EXSCEL Study Group
Circulation 2017;136:24:
[Abstract]

Association of British Clinical Diabetologists (ABCD) Autumn Meeting 2016, Brighton
Estimating the potential risk reduction of Type 2 diabetes mellitus (T2DM) complications if systolic blood pressure (SBP) targets were to be lowered
S Mostafa, RL Coleman, OF Agbaje, A Gray, RR Holman, MA Bethel
The British Journal of Diabetes 2017;17:1:42
[Abstract]

Quality of Care and Outcomes Research (QCOR) Scientific Sessions 2017, Arlington
Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes: International Insights From the TECOS Trial
Neha J Pagidipati, Ann Marie Navar, Karen S Pieper, Jennifer B Green, M. A Bethel, Paul W Armstrong, Robert G Josse, Darren K McGuire, Yuliya Lokhnygina, Jan H Cornel, Sigrun Halvorsen, Timo E Strandberg, Tuncay Delibasi, Rury R Holman, Eric D Peterson, on behalf of the TECOS Study Group
Circulation 2017;10:Suppl 3:
[Abstract]

European Society of Cardiology (ESC) Congress 2017,
Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes: International Insights From the TECOS Trial
Neha J Pagidipati, Ann Marie Navar, Karen S Pieper, Jennifer B Green, M. A Bethel, Paul W Armstrong, Robert G Josse, Darren K McGuire, Yuliya Lokhnygina, Jan H Cornel, Sigrun Halvorsen, Timo E Strandberg, Tuncay Delibasi, Rury R Holman, and Eric D Peterson, on behalf of the TECOS Study Group
Circulation 2017;10:Suppl 3:
[Abstract]

Francophone Society of Diabetes Annual Congress 2017, Lille
Evaluation of the Safety Profile of Sitagliptin in Older Adults in the TECOS Cardiovascular Safety Trial
Angelyn Bethel, Samuel Engel, Jennifer Green, Zhen Huang, Keith Kaufman, Eberhard Standl, Shailaja Suryawanshi, Frans Van de Werf, Eric Peterson, Rury Holman
Diabetes and Metabolism 2017;43:2 Suppl:A55-A56

Francophone Society of Diabetes Annual Congress 2017, Lille
Impact on cardiovascular events and tolerance of sitagliptin in insulin-treated patients with type 2 diabetes: the TECOS experiment
Angelyn Bethel, Sam Engel, Jie Ding, Robert Josse, Rury Holman
Diabetes and Metabolism 2017;43:2 Suppl:A56

Francophone Society of Diabetes Annual Congress 2017, Lille
Differences Between Men and Women in the Cardiovascular Safety Test of Sitagliptin (TECOS)
Jennifer Green, Joakim Alfredsson, Susanna Stevens, Shelby Reed, Darren McGuire, Paul Armstrong, Sam Engel, Angelyn Bethel, Frans Van de Werf, Eric Peterson, Rury Holman
Diabetes and Metabolism 2017;43:2 Suppl:A56

American Diabetes Association (ADA) Conference, San Diego-P
Medical Resource Use and Costs in Patients with Type 2 Diabetes Mellitus during the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
SHELBY D. REED, YANHONG LI, JOSE LEAL, FELICIA GRAHAM, JOAKIM ALFREDSSON, ALASTAIR M. GRAY, JOHN B. BUSE, JENNIFER B. GREEN, KEITH D. KAUFMAN, AXEL RIEFFLIN, SHAILAJA SURYAWANSHI, FRANS VAN DE WERF, ERIC D. PETERSON, RURY R. HOLMAN, TECOS STUDY GROUP
Diabetes 2017;66:(Suppl 1):A697-A750.
[Abstract]

American Diabetes Association (ADA) Conference, San Diego
Time to Insulin in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
M A BETHEL, SAMUEL S ENGEL, JYOTSNA GARG, SUSANNA R STEVENS, YULIYA LOKHNYGINA, ROBERT G JOSSE, JENNIFER B GREEN, ERIC D PETERSON, RURY R HOLMAN, TECOS STUDY GROUP
Diabetes 2017;66:(Suppl 1):1183-P
[Abstract]

American Diabetes Association (ADA) Conference, San Diego
Emerging Sitagliptin Benefit for All-Cause Hospitalizations: Evidence from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
SHELBY D REED, YANHONG LI, JOSE LEAL, FELICIA GRAHAM, JOAKIM ALFREDSSON, ALASTAIR M GRAY, JOHN B BUSE, JENNIFER B GREEN, KEITH D KAUFMAN, AXEL RIEFFLIN, SHAILAJA SURYAWANSHI, FRANS VAN DE WERF, ERIC D PETERSON, RURY R HOLMAN, FOR THE TECOS STUDY
Diabetes 2017;66:(Suppl 1):1344-P